1. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
- Author
-
Milone, Giuseppe, Martino, Massimo, Leotta, Salvatore, Spadaro, Andrea, Zammit, Valentina, Cupri, Alessandra, Avola, Giuseppe, Camuglia, Maria Grazia, Di Marco, Annalia, Scalzulli, Potito, Morelli, Mara, Olivieri, Attilio, and Tripepi, Giovanni
- Subjects
- *
MULTIPLE myeloma treatment , *MULTIPLE myeloma , *CANCER chemotherapy , *STEM cell transplantation , *CYCLOPHOSPHAMIDE , *PATIENTS - Abstract
We here report final results of a phase II/III prospective study that evaluated in Multiple Myeloma the use of on-demand plerixafor (PLX) added to mobilizing chemotherapy for patients showing predictive signs of mobilization failure. A total of 111 patients with MM were registered, all received cyclophosphamide 4 g/m2and granulocyte colony-stimulating factor (G-CSF). Overall, a successful CD34+ cell mobilization was achieved in 97.2% (108/111) of patients. Minimum harvest (≥2.0 × 106CD34+ cells/kg) was achieved in 97.2% (108/111) and optimal harvest success (≥4.0 × 106CD34+ cells/kg) was achieved in 84.6% (94/111). Multivariate analysis showed that patients who received on-demand PLX treatment had significantly higher likelihoods of successfully achieving both the minimal (p = .006) and optimal harvest (p = .05) in respect to a historical control group mobilized without any PLX. The incremental cost-effectiveness ratio, for each 1% increase in probability of achieving a successful minimal harvest, was€40.6 per patient. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF